📰 Nasdaq Evfm News
Nasdaq Evfm News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Evfm. Real-time updates on events, politics, business and more.
December 17, 2023
Laidlaw reissued their hold rating on shares of Evofem Biosciences (NASDAQ:EVFM – Free Report) in a report published on Wednesday, Benzinga reports. Evofem Biosciences Trading Down 23.5 % Shares of EVFM stock opened at $0.07 on Wednesday. The stock has a 50 day moving average of $0.08 and a 200 day moving average of $0.35. […]
November 17, 2023
Evofem Biosciences (NASDAQ:EVFM – Get Free Report) posted its quarterly earnings data on Tuesday. The biotechnology company reported $0.10 EPS for the quarter, reports. Evofem Biosciences had a net margin of 344.82% and a negative return on equity of 77.85%. The firm had revenue of $5.11 million for the quarter. Evofem Biosciences Trading Down 10.6 […]
June 4, 2022
Equities analysts predict that Evofem Biosciences, Inc. (NASDAQ:EVFM – Get Rating) will report sales of $6.65 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Evofem Biosciences’ earnings. The lowest sales estimate is $5.50 million and the highest is $8.56 million. Evofem Biosciences reported sales of $1.86 million in the […]
June 2, 2022
Investment analysts at Laidlaw assumed coverage on shares of Evofem Biosciences (NASDAQ:EVFM – Get Rating) in a research note issued on Thursday, The Fly reports. The brokerage set a “buy” rating on the biotechnology company’s stock. Separately, Morgan Stanley boosted their price target on Evofem Biosciences from $7.95 to $8.55 and gave the company an […]
June 1, 2022
Evofem Biosciences, Inc. (NASDAQ:EVFM – Get Rating) CEO Saundra L. Pelletier purchased 141,000 shares of the firm’s stock in a transaction that occurred on Friday, May 27th. The stock was bought at an average cost of $0.35 per share, for a total transaction of $49,350.00. Following the purchase, the chief executive officer now owns 236,722 […]
April 24, 2022
Brokerages expect that Evofem Biosciences, Inc. (NASDAQ:EVFM – Get Rating) will post $4.23 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Evofem Biosciences’ earnings. The highest sales estimate is $5.30 million and the lowest is $3.30 million. Evofem Biosciences posted sales of $1.11 million during the […]
March 16, 2022
Equities analysts expect that Evofem Biosciences, Inc. (NASDAQ:EVFM – Get Rating) will report sales of $4.40 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Evofem Biosciences’ earnings, with the highest sales estimate coming in at $5.30 million and the lowest estimate coming in at $3.51 million. Evofem Biosciences posted […]